진행성 비소세포 폐암에 대한 Cisplatin, Etoposide, Vinblastine (PEV) 3제 복합 화학 요법
Combination Chemotherapy with Cisplatin, Etoposide, and Vinblastine (PEV) in the Advanced Non-Small Cell Lung Cancer
박근철, 강윤구, 신동복, 김시영, 방영주, 한성구, 심영수,
소속 상세정보
박근철 ( )
서울대학교 의과대학 내과학교실
강윤구 ( )
서울대학교 의과대학 내과학교실
신동복 ( )
서울대학교 의과대학 내과학교실
김시영 ( )
서울대학교 의과대학 내과학교실
방영주 ( )
서울대학교 의과대학 내과학교실
한성구 ( )
서울대학교 의과대학 내과학교실
심영수 ( )
서울대학교 의과대학 내과학교실
KMID : 0360319890210010082
Abstract
Fifty patients with the advanced non-small cell lung cancer, who had no previous treatment, were treated with a combination chemotherapy regimen consisting of cisplatin (20 mg/㎡ i.v. day 1~5), etoposide (100 mg/㎡ i.v. day 2~4), and vinblastine (6 mg/㎡ i.v. day 1) every 3 weeks. Among the 50 patients entered into this study 45 patients were evaluable for response. Objective responses were achieved in 49 % (22/45) of patients (2 CRs, 20 PRs). In 23 patients with limited disease, the response rate was 61% (14/23) with no complete response, higher than that, but not statistically significant, in the extensive disease patients (36% with 2 CRs). The overall median survival of the patients was 42.6 weeks and the responding patients survived longer than non-responders (median survival; 51.5 weeks vs. 37.4 weeks, p<0.05). Toxicity with this regimen was acceptable; myelosuppression was the major toxic effect and was severe in only 11% of the patients with one treatment-related death from sepsis associated with granulocytopenia. The gastrointestinal side effects and alopecia were rather universal and the peripheral neuropathy (20%) and azotemia (9%) were not uncommon, but manageable in general.
키워드
원문 및 링크아웃 정보
등재저널 정보